5-HT4 agonist shows promise in gastroparesis

09:53 EDT 4 Aug 2017 | Healio

Velusetrag safely improved symptoms and normalized gastric emptying in both diabetic and idiopathic gastroparesis in a phase 2b trial, the manufacturer announced.Velusetrag (TD-5108; Theravance Biopharma) is an oral 5-hydroxytryptamine receptor 4 agonist in development for GI motility disorders. It was fast-tracked by the FDA for gastroparesis in December 2016.

Original Article: 5-HT4 agonist shows promise in gastroparesis


More From BioPortfolio on "5-HT4 agonist shows promise in gastroparesis"

Quick Search

Relevant Topic

Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...